Drug Pricing Push: Trump announced nine more “most-favored-nation” deals with mid-sized pharma, bringing participation to 26 companies and claiming coverage of 89% of branded drugs—aimed at lowering Medicaid prices and boosting U.S. access to newer medicines. Cancer Trial Updates: Final COMBI-I results show spartalizumab plus dabrafenib/trametinib improved overall survival in BRAF V600-mutant melanoma, with higher rates of fever and treatment-related side effects. Breast Cancer Care: New expert discussion highlights how second-line choices in HR+/HER2− metastatic breast cancer hinge on progression timing, disease burden, performance status, and repeat biomarker testing (including ctDNA and tissue reassessment). Cardiovascular Outcomes: VESALIUS-CV analysis reports evolocumab reduced all-cause death by 20% in high-risk patients without prior heart attack or stroke. HIV Treatment: FDA approved Bixlenvo as a once-daily complete switch regimen for virologically suppressed adults with HIV-1. Veterinary Safety: Revival Animal Health recalled certain feline milk replacers after tests found low essential vitamins and minerals for newborn kittens. Medical Tourism: South Korea saw foreign spending on medical services jump 66.5% in July, led by dermatology and plastic surgery. Care Delivery Innovation: A UNC telehealth rapid access prostate cancer program cut referral-to-biopsy time from 161 to 71 days.